Navigation Links
CorVel Announces Record Earnings
Date:6/10/2008

s release speak only as of the date they are made. The Company undertakes no obligation to revise or update publicly any forward-looking statement for any reason.

CorVel Corporation

Quarterly Results - Income Statement

Quarters and Fiscal Years Ended March 31, 2007 and 2008

Quarter Ended Quarter Ended

March 31, 2007 March 31, 2008

Revenues 70,910,000 77,368,000

Cost of revenues 53,330,000 56,538,000

Gross profit 17,580,000 20,830,000

General and administrative 8,911,000 10,661,000

Income from operations 8,669,000 10,169,000

Income tax expense 3,381,000 3,965,000

Net income 5,288,000 6,204,000

Earnings Per Share:

Basic $0.38 $0.45

Diluted $0.37 $0.44

Weighted Shares

Basic 14,009,000 13,758,000

Diluted 14,305,000 13,958,000

Fiscal Year Ended Fiscal Year Ended

March 31, 2007 March 31, 2008

Revenues 274,581,000 301,894,000

Cost of revenues 208,746,000 223,829,000

Gross profit 65,835,000 78,065,000

General and administrative 35,383,000 39,720,000

Income from operations 30,452,000 38,345,000

Income tax expense 11,876,
'/>"/>

SOURCE CorVel Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. CorVel Announces Appearance at Bank of America Health Care Conference
2. CorVel to Present at UBS Global Healthcare Services Conference
3. CorVel Announces Record Earnings Per Share
4. CorVel Corporation Announces Resumption of Stock Repurchases
5. SUA Insurance Company Announces Partnership With American Safety Indemnity Company
6. WellPoint Announces Appearance at Upcoming Conference
7. MINRAD International, Inc. Announces FDA Approval of Petrem(TM) Sevoflurane
8. Synthetech Announces Appointment of Dr. Gregory R. Hahn as President and Chief Executive Officer
9. Mylan Announces Final FDA Approval for Zaleplon Capsules
10. PharMEDium Announces National Rollout of Electronic 222 Ordering Initiative
11. Senetek PLC Announces Key Personnel Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Torchmark Corporation Declares Dividend 2Health News:America's Pending Shortage of Cancer Doctors 2Health News:America's Pending Shortage of Cancer Doctors 3Health News:Preeclampsia Might Protect Against Testicular Cancer 2Health News:Preeclampsia Might Protect Against Testicular Cancer 3Health News:New Online Support Site Offers Hope, Information, and Help for Patients Who Have Suffered a Catastrophic Injury 2Health News:Media Affects Public Perception of Infectious Diseases 2Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 2Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 3Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 4Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 5Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 6Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 7Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 8Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 9Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 10Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 11Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 12Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 13Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 14Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 15Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 16Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 17Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 18Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 19Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 20Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 21Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 22Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 23Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 24Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 25Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 26Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 27Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 28Health News:Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1): 29
Breaking Medicine Technology:ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Qforma Appoints Erin McLaughlin as Director Field Operations 5834 1Qforma Appoints Erin McLaughlin as Director Field Operations 5834 2Webcast Alert 3A Transgenomic Inc Announces Third Quarter 2009 Earnings Release Conference Call Webcast 5832 1Webcast Alert 3A Transgenomic Inc Announces Third Quarter 2009 Earnings Release Conference Call Webcast 5832 2High Resolution Breast PET Improves Breast Cancer Detection 5830 1High Resolution Breast PET Improves Breast Cancer Detection 5830 2High Resolution Breast PET Improves Breast Cancer Detection 5830 3